Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure Chronic Clear all
Completed Phase 2 Interventional

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

NCT04075916
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome

NCT01029587
View directory record Official record
Conditions
Antiphospholipid Antibody Syndrome, End Stage Renal Disease
Interventions
Eculizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)

NCT02790606
View directory record Official record
Conditions
Stenosis, Restenosis
Interventions
Covera(TM) Vascular Covered Stent
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 23, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

TARGTEPO Treatment for Anemia in PD US Trial

NCT02468414
View directory record Official record
Conditions
Anemia of End Stage Renal Disease
Interventions
MDGN201 TARGTEPO
Biological
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional

The Optiflow Patency and Maturation Study

NCT01921933
View directory record Official record
Conditions
End-stage Kidney Disease, End-stage Renal Disease
Interventions
Optiflow
Device
Lead sponsor
Bioconnect Systems, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

NCT05182840
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

NCT00511225
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
cholecalciferol, placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

NCT00646035
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
paricalcitol capsules
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2008 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UF profiling during HD, Conventional HD
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Carrboro, North Carolina • Siler City, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis

NCT00618475
View directory record Official record
Conditions
End Stage Renal Disease, Depression
Interventions
Cognitive behavioral therapy
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 23, 2026, 6:53 PM EDT
Terminated Not applicable Interventional

Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria

NCT04171778
View directory record Official record
Conditions
Chronic Kidney Disease Stage 3B, Chronic Kidney Disease, Stage 4, Proteinuria
Interventions
whole food, plant-based diet
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 23, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

NCT01537315
View directory record Official record
Conditions
Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions
Hydroxychloroquine, Matching Placebo
Drug · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

NCT00732069
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions
Placebo, Ramipril, Valsartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 23, 2026, 6:53 PM EDT
Completed No phase listed Observational

Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease

NCT01114594
View directory record Official record
Conditions
Chronic Kidney Disease, Polycystic Kidney, Autosomal Dominant
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Tele-palliative Care in Rural Dialysis Patients

NCT03744117
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Palliative care consultation
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

NCT02743897
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Zepatier, Mavyret
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105

NCT03043482
View directory record Official record
Conditions
Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Interventions
Single VS-105/placebo to healthy, Multiple VS-105/placebo to healthy, Multiple VS-105/placebo to HD subjects
Drug
Lead sponsor
Vidasym, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 23, 2026, 6:53 PM EDT
Recruiting No phase listed Observational

Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)

NCT07059962
View directory record Official record
Conditions
Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
Interventions
Bodyport Cardiac Scale
Device
Lead sponsor
Bodyport Inc.
Industry
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Victorville, California • Augusta, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Lifestyle Management of CKD in Obese Diabetic Patients

NCT02276742
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions
Social Cognitive Theory, Monitoring
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 23, 2026, 6:53 PM EDT
Not listed No phase listed Observational

Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy

NCT02994303
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
1 Day to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Decatur, Georgia • Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

NCT02360644
View directory record Official record
Conditions
Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
Aurora, Colorado • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 23, 2026, 6:53 PM EDT
Withdrawn Phase 4 Interventional

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

NCT06995144
View directory record Official record
Conditions
Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
Interventions
Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT03617536
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 23, 2026, 6:53 PM EDT